Advanced NSCLC Combination Treatment

Immune-Mediated
Adverse
Reactions

Immune-mediated adverse reactions on therapy with LIBTAYO1*

The safety of LIBTAYO was evaluated in 810 patients with advanced solid malignancies1

Adverse reactions, % (N=810)
Pneumonitis
3.2
2.1
0.5
0.5
NR
1.4
2.1
100
58
Colitis
2.2
1.1
0.9
NR
NR
0.4
1.5
100
39
Hepatitis
2
0.2
1.4
0.1
0.1
1.2
0.5
100
50
Endocrinopathies
Adrenal insufficiency
0.4
NR
0.4
NR
NR
0.1
0
100
0
Hypophysitis
0.4
0.1
0.2
NR
NR
0.1
0.1
67
0
Thyroiditis§
0.6
0.2
NR
NR
NR
0
0.1
0
0
Hyperthyroidism
3.2
0.9
NR
NR
NR
0
0.5
3.8
50
Hypothyroidism||
7
6
NR
NR
NR
0.1
1.1
0
8.3
Type 1 diabetes mellitus
0.1
NR
NR
0.1
NR
0
0.1
NR
NR
Nephritis with renal dysfunction
0.6
0.4
0.1
NR
0.1
0.1
0.4
100
80
Dermatologic#
1.6
0.6
0.9
NR
NR
0.1
1.4
100
69
Other imARs**
<1%
for each
NR
NR
NR
NR
NR
NR
NR
NR

The incidence and severity of immune-mediated adverse reactions were similar when LIBTAYO was administered as a single agent or in combination with chemotherapy.